KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib Presented ByProf. Jens Bedke, University of Tübingen, Germany TrialPhase 3, KEYNOTE-426 ConferenceEAU 2020 20 August, 2020 10:41